3 hours ago
1
hapabapa
- TD Cowen has initiated Bio-Techne (NASDAQ:TECH) with a buy rating saying the diagnostics supplier's "current valuation doesn't reflect the strong organic growth and margin opportunity."
- The firm set a price target of $65 (~23% upside based on July 8 close).
English (US) ·